NASDAQ:RGLS - Regulus Therapeutics Stock Price, News, & Analysis

$0.97
-0.03 (-3.00 %)
(As of 06/16/2019 04:00 PM ET)
Today's Range
$0.95
Now: $0.9698
$1.05
50-Day Range
$0.8978
MA: $1.18
$1.50
52-Week Range
$0.80
Now: $0.9698
$9.00
Volume201,282 shs
Average Volume221,003 shs
Market Capitalization$19.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGLS
CUSIP75915K10
Phone858-202-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$70,000.00
Book Value($0.67) per share

Profitability

Net Income$-48,710,000.00
Net Margins-526.10%
Return on Equity-186,717.70%

Miscellaneous

Employees24
Market Cap$19.93 million
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable

Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc (NASDAQ:RGLS) released its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.84. The biopharmaceutical company had revenue of $6.78 million for the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative net margin of 526.10% and a negative return on equity of 186,717.70%. View Regulus Therapeutics' Earnings History.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Regulus Therapeutics.

What price target have analysts set for RGLS?

5 brokers have issued 1-year price objectives for Regulus Therapeutics' shares. Their predictions range from $0.50 to $1.50. On average, they anticipate Regulus Therapeutics' stock price to reach $1.00 in the next year. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Price Targets for Regulus Therapeutics.

What is the consensus analysts' recommendation for Regulus Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regulus Therapeutics.

What are Wall Street analysts saying about Regulus Therapeutics stock?

Here are some recent quotes from research analysts about Regulus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (3/29/2019)
  • 2. Needham & Company LLC analysts commented, "Regulus announced this morning another revision to the Sanofi collaboration agreement, in which Sanofi has been granted a WW exclusive license to RG-012. Sanofi will now assume control of the development program, including all costs going forward. Regulus will receive $7M upfront and is entitled to $40M in development milestone payments. Regulus had suspended enrollment in the Phase 2 RG-012 program in Alport Syndrome earlier this year in order to conserve cash while renegotiating terms with Sanofi. The transaction extends cash to 2Q19, but under new terms, Regulus will not be receiving any revenue from the program after Phase 2 is completed by Sanofi." (11/6/2018)
  • 3. Wedbush analysts commented, "We believe this move will likely create some investor/analyst churn in the near term but will open up capital allocation and capacity to focus on the growing CHCA and CHCI segments in the longer term. Although the sale will likely take a couple quarters to complete, we believe this shift will attract a more consumer focused investor base lead to upside from the weak share performance following the report. As such, we remain BUY rated on PRGO shares." (8/10/2018)

Has Regulus Therapeutics been receiving favorable news coverage?

Media coverage about RGLS stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Regulus Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Regulus Therapeutics.

Who are some of Regulus Therapeutics' key competitors?

What other stocks do shareholders of Regulus Therapeutics own?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the folowing people:
  • Mr. Joseph P. Hagan, Pres, CEO & Director (Age 50)
  • Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)
  • Mr. Christopher Ray Aker J.D., VP of Legal Affairs & Corp. Sec.
  • Mr. Turner Jenkins, Director & Head of Corp. Devel.

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.62%) and Wedbush Securities Inc. (0.40%). Company insiders that own Regulus Therapeutics stock include Christopher Ray Aker, Daniel R Chevallard, Joseph P Hagan, Kathryn J Collier, Pascale Witz, Peter J Barris, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.

Which institutional investors are buying Regulus Therapeutics stock?

RGLS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Wedbush Securities Inc.. Company insiders that have bought Regulus Therapeutics stock in the last two years include Daniel R Chevallard, Joseph P Hagan, Kathryn J Collier, Pascale Witz, Peter J Barris, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $0.9698.

How big of a company is Regulus Therapeutics?

Regulus Therapeutics has a market capitalization of $19.93 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-48,710,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis. Regulus Therapeutics employs 24 workers across the globe.View Additional Information About Regulus Therapeutics.

What is Regulus Therapeutics' official website?

The official website for Regulus Therapeutics is http://www.regulusrx.com/.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]


MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  261 (Vote Underperform)
Total Votes:  660
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe RGLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel